WALTHAM, Mass. — FluidForm Bio, a leader in developing life-like human tissue to treat disease, shares recent advancements in building human cardiac tissues using FRESH™ 3D bioprinting. Recently published in APL Bioengineering, the research article FRESH™ 3D bioprinted cardiac tissue, a bioengineered platform for in vitro pharmacology addresses the critical need for a predictive model of human cardiac physiology in drug development. There are significant gaps in existing models due to their incomplete recapitulation of adult human cardiovascular physiology. FluidForm Bio has demonstrated potential for bridging this gap using human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) in three-dimensional tissue structure. [Read more…]
Century Therapeutics and FUJIFILM Cellular Dynamics to Commercialize iPSC-Derived Cell Therapies in Autoimmune and Inflammatory Diseases
NOVEMBER 9, 2023, PHILADELPHIA and MADISON, Wis., – Century Therapeutics, Inc. (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immune-oncology, and FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human iPSCs and iPSC-derived cells, today announce a new worldwide license agreement and expansion of existing licenses for the development and commercialization of cell therapies derived from iPSCs for the treatment of autoimmune and inflammatory diseases, including type 1 diabetes, multiple sclerosis, lupus, and rheumatoid arthritis. [Read more…]
Century Therapeutics Progressing CNTY-101, its iPSC-derived CAR NK Cell Candidate, Into a Phase 1 Trial
Represents second IND clearance for CNTY-101, the Company’s lead iPSC-derived CD19-targeted CAR NK cell product candidate, and first in an autoimmune and inflammatory disease indication
Company plans to initiate the Phase 1 clinical trial in the first half of 2024; initial data expected by year-end 2024
CNTY-101 is the first cell therapy product candidate engineered with six precision gene edits including a CD19-CAR, Allo-Evasion™ technology, IL-15 cytokine support and a safety switch
GMP cell CDMO I Peace, Inc. obtains accreditation as ISO 17025: 2017 compliant
Starts undertaking quality evaluation and characterization of iPSCs in accordance with ISO standards
PALO ALTO, Calif., Dec. 6, 2023 — Leading GMP cell CDMO I Peace, Inc., specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that its Palo Alto quality control testing facility has been accredited as ISO 17025: 2017 compliant. The accreditation was certified by ANSI National Accreditation Board, one of the leading accreditation bodies in the world. The tests in the scope of accreditation center on the characterization of iPSCs and include cell count and viability per USP <1046>, detection of pluripotency marker expression by flow cytometry per USP <1027>, and also by immunofluorescence assay. [Read more…]
Seattle Children’s launches BrainChild Bio to accelerate CAR T-cell therapies for children with brain tumors
BrainChild Bio’s initial CAR T-cell therapy program will focus on advancing ongoing clinical trials evaluating safety and efficacy in pediatric brain tumors.
December 5, 2023, Seattle, WA – Seattle Children’s announced the launch of BrainChild Bio, Inc. to accelerate the advancement of chimeric antigen receptor (CAR) T-cell therapies in Central Nervous System (CNS) tumors. BrainChild Bio will be granted an exclusive license to novel CAR T-cell technology for CNS tumors developed at Seattle Children’s and will build upon the pioneering CAR T-cell therapy and clinical translational work of Michael Jensen, M.D., and his team at Seattle Children’s Therapeutics. Seattle Children’s has provided the initial equity funding for BrainChild Bio which will operate as an independently managed corporation. [Read more…]
- « Previous Page
- 1
- …
- 104
- 105
- 106
- 107
- 108
- …
- 334
- Next Page »